Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 86. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Multidisciplinary care for amyotrophic lateral sclerosis1132
Correction to Lancet Neurol 2021; 20: 448–59959
Correction to Lancet Neurol 2024; 23: 168–77875
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease743
Traumatic brain injury research: homogenising heterogeneity715
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study652
Increasing diversity in dementia research545
The predictive value and clinical use of the neurological pupillary index – Authors' reply498
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply496
Lessons and future directions for GBA1-targeting therapies478
Correction to Lancet Neurol 2022; 21: 42–52466
Implications of the KIWE trial for low-income and lower-middle-income countries440
Correction to Lancet Neurol 2020; 19: 391–401397
Correction to Lancet Neurol 2025; 24: 850–65396
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r363
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease350
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study349
Dementia diagnosis in the anti-amyloid era307
Global burden of stroke: dynamic estimates to inform action292
Anti-CD19 CAR T cells for refractory myasthenia gravis267
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study253
RAB32 mutation in Parkinson's disease250
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial247
The relevance of social and commercial determinants for neurological health242
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study228
Management of atherosclerotic extracranial carotid artery stenosis225
A biological classification of Huntington's disease: the Integrated Staging System208
Surrogate endpoints for progressive multifocal leukoencephalopathy202
The prescription of valproate: risk of harm196
Diana Cejas193
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply191
Considering the neurological health needs of LGBTQIA people190
Elia M Pestana Knight187
Beyond the modular brain183
Aspiring to restore arm and hand function after stroke183
Albert Kwaku Akpalu168
A sensitive portrayal of a controversial condition166
A chilly tale of dementia163
A nasal CGRP receptor antagonist for acute migraine therapy162
A study in healing the wounds of trauma160
Trials in intracerebral haemorrhage: a path to success?157
Correction to Lancet Neurol 2023; 22: 812–25155
Delving into the human mind155
Correction to Lancet Neurol 2022; 21: 284–94154
From stroke awareness to stroke action awareness153
Amyotrophic lateral sclerosis from genotoxins alone?140
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment138
Epilepsy syndromes: an essential piece of the puzzle136
Development of treatments for Down syndrome127
Gene therapy for X-linked myotubular myopathy: the challenges124
Global burden of headache disorders: innovations, disparities, and priorities for action124
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial123
2025 for neuromuscular diseases: a year of multiple advances123
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri122
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases120
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial120
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment119
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro117
Parkinson's disease is a recognisable and useful diagnostic entity115
Movement disorders research in 2021: cracking the paradigm114
Functional or hysterical?113
Cognitive function in people with functional seizures111
A proposal for equity neuroscience110
Rethinking AI trials in brain health108
Changing multiple-sclerosis-induced thoughts and behaviours107
Supporting young carers across neurological disorders106
Learning to be an adult with a disability104
Revisiting candesartan: new evidence for an old option in migraine prevention103
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response103
Multiple sclerosis in 2022: old players, new insights102
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers100
Riluzole and spinocerebellar ataxia type 2: the ATRIL trial99
New results for risdiplam in spinal muscular atrophy98
Expansion of stenting indications in the USA93
Correction to Lancet Neurol 2024; 23: 110–2293
Responsible innovation in neurology93
Jessica Ailani92
Correction to Lancet Neurol 2022; 21: 620–3192
Encephalitis awareness: our ambitious global endeavour91
Brain health in the Philippines91
Neurological infections in 2023: surveillance and prevention91
Major advances in Parkinson's disease over the past two decades and future research directions89
Detection of ionising radiation by the CNS: a case report87
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial87
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study86
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial86
0.86311197280884